Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.

[1]  W. Cooper,et al.  Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status , 2020, Journal of Clinical Pathology.

[2]  A. Nicholson,et al.  Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  J. Lea,et al.  PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma , 2020, The American journal of surgical pathology.

[4]  L. Pusztai,et al.  Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer , 2020, Modern Pathology.

[5]  M. Tsao,et al.  Canadian Multicentre Project on Standardization of PD-L1 22C3 Immunohistochemistry Laboratory Developed Tests for Pembrolizumab Therapy in Non-Small Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  P. Ramos-García,et al.  An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. , 2020, Oral diseases.

[7]  G. Ferraccioli,et al.  Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): Tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations. , 2020, Clinical immunology.

[8]  Lianhong Li,et al.  PD-1/PD-L1 pathway: current researches in cancer. , 2020, American journal of cancer research.

[9]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[10]  A. Psyrri,et al.  Biomarkers for immunotherapy response in head and neck cancer. , 2020, Cancer treatment reviews.

[11]  K. Kerr,et al.  Cytology for PD-L1 testing: A systematic review. , 2020, Lung cancer.

[12]  K. Molberg,et al.  Effects of Decalcifying Agents of Variable Duration on PD-L1 Immunohistochemistry. , 2020, American journal of clinical pathology.

[13]  N. Girard,et al.  PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  J. Cheville,et al.  Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma , 2019, Cancer medicine.

[15]  S. Fox,et al.  Adequate tumour cellularity is essential for accurate PD‐L1 immunohistochemistry assessment on cytology cell‐block specimens , 2019, Cytopathology : official journal of the British Society for Clinical Cytology.

[16]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[17]  A. Lopez‐Beltran,et al.  PD-L1 assessment in urothelial carcinoma: a practical approach. , 2019, Annals of translational medicine.

[18]  Y. Ohe,et al.  A minimum of 100 tumor cells in a single biopsy sample is required to assess programmed cell death ligand 1 expression in predicting patient response to nivolumab treatment in non-squamous non-small cell lung carcinoma. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  M. Copin,et al.  P2.09-17 Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative , 2019, Journal of Thoracic Oncology.

[20]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[21]  K. Rabe,et al.  Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients , 2019, Virchows Archiv.

[22]  Chao Li,et al.  “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy , 2019, Modern Pathology.

[23]  N. Rizvi,et al.  Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  M. Dietel,et al.  Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study. , 2019, Lung cancer.

[25]  Matthew W. Anderson,et al.  Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine. , 2019, Archives of pathology & laboratory medicine.

[26]  Yan Zhang,et al.  T Cell Dysfunction in Cancer Immunity and Immunotherapy , 2019, Front. Immunol..

[27]  R. Ferris,et al.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) , 2019, Journal of Immunotherapy for Cancer.

[28]  V. Reuter,et al.  PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology , 2019, The American journal of surgical pathology.

[29]  E. Thunnissen,et al.  Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen , 2019, Virchows Archiv.

[30]  R. Scolyer,et al.  Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. , 2019, Oral oncology.

[31]  Sung-Bae Kim,et al.  Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study , 2019, JAMA oncology.

[32]  Y. Bang,et al.  Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study , 2019, Gastric Cancer.

[33]  H. Puhr,et al.  New emerging targets in cancer immunotherapy: the role of LAG3 , 2019, ESMO Open.

[34]  E. V. Van Allen,et al.  Genomic correlates of response to immune checkpoint blockade , 2019, Nature Medicine.

[35]  F. Pacini,et al.  Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer , 2019, Endocrine.

[36]  S. Sudarsanam,et al.  Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases , 2019, Modern Pathology.

[37]  Yan Lu,et al.  Analysis of PD-L1 expression in trophoblastic tissues and tumors. , 2019, Human pathology.

[38]  Li Wu,et al.  PD-1/PD-L1 Inhibitors in Cervical Cancer , 2019, Front. Pharmacol..

[39]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[40]  E. Elgabry,et al.  Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study , 2019, JAMA oncology.

[41]  H. Schildhaus,et al.  Der prädiktive Wert der PD-L1-Diagnostik , 2018, Der Pathologe.

[42]  L. Mariani,et al.  Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[44]  E. Thunnissen.  How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer. , 2018, Archives of pathology & laboratory medicine.

[45]  Hui Yu,et al.  PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[47]  M. Lee,et al.  Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis , 2018, Scientific Reports.

[48]  Toyoaki Hida,et al.  Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  K. Higgins,et al.  PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma , 2018, The American journal of surgical pathology.

[50]  L. Marchionni,et al.  PD‐L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  V. Iyer,et al.  Programmed death‐ligand 1 immunoexpression in matched biopsy and liquid‐based cytology samples of advanced stage non‐small cell lung carcinomas , 2018, Cytopathology : official journal of the British Society for Clinical Cytology.

[52]  J. Lunceford,et al.  Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. , 2018, Archives of pathology & laboratory medicine.

[53]  C. D'Arrigo,et al.  Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms , 2018, Modern Pathology.

[54]  K. Tamura,et al.  Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers. , 2018 .

[55]  N. Le Stang,et al.  Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  D. Clark.  Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology , 2018, Cancer cytopathology.

[57]  A. Gown,et al.  Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression , 2017, Modern Pathology.

[58]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[59]  Ross A Soo,et al.  De-novo and acquired resistance to immune checkpoint targeting. , 2017, The Lancet. Oncology.

[60]  S. Fox,et al.  Comparison of Four PD‐L1 Immunohistochemical Assays in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[61]  T. Powles,et al.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[62]  E. Smit,et al.  PD-L1 IHC in NSCLC with a global and methodological perspective. , 2017, Lung cancer.

[63]  J. Heymann,et al.  PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens , 2017, Cancer cytopathology.

[64]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[65]  B. Skov,et al.  Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[66]  J. Taube,et al.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[67]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[68]  A. Borczuk,et al.  Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. , 2017, Archives of pathology & laboratory medicine.

[69]  R. Røge,et al.  Accurate PD-L1 Protocols for Non–Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3 , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[70]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[71]  S. Fox,et al.  Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[72]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[73]  K. Emancipator,et al.  Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[75]  Arash Salmaninejad,et al.  PD-1/PD-L and autoimmunity: A growing relationship. , 2016, Cellular immunology.

[76]  J. Sandbank,et al.  A Harmonization Study for the Use of 22C3 PD‐L1 Immunohistochemical Staining on Ventana’s Platform , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[77]  D. Rimm,et al.  Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer , 2016, Modern Pathology.

[78]  B. Rose,et al.  PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials , 2016, Oncotarget.

[79]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[80]  Nicole Schechter,et al.  Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma , 2016, Diagnostic Pathology.

[81]  R. Trisolini,et al.  Fading With Time of PD-L1 Immunoreactivity in Non–Small Cells Lung Cancer Tissues: A Methodological Study , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[82]  Jonathan R. Clark,et al.  Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. , 2016, Pathology.

[83]  E. Smyth,et al.  Immunotherapy for Gastroesophageal Cancer , 2016, Journal of clinical medicine.

[84]  N. Chen,et al.  Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer , 2016, Scientific Reports.

[85]  P. Jänne,et al.  Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[86]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[87]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[88]  M. Salto‐Tellez,et al.  Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics , 2015, Journal of Clinical Pathology.

[89]  J. Madore,et al.  PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials , 2015, Pigment cell & melanoma research.

[90]  C. Gilks,et al.  Standardization of Positive Controls in Diagnostic Immunohistochemistry: Recommendations From the International Ad Hoc Expert Committee , 2015 .

[91]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[92]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[93]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[94]  Helen M. Moore,et al.  A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? , 2014, Archives of pathology & laboratory medicine.

[95]  L. Bradley,et al.  Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. , 2014, Archives of pathology & laboratory medicine.

[96]  Lei Lu,et al.  Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs , 2014, Journal of Translational Medicine.

[97]  R. Scolyer,et al.  Data Set for Pathology Reporting of Cutaneous Invasive Melanoma , 2013, The American journal of surgical pathology.

[98]  F. Hodi,et al.  Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 , 2012, Clinical Cancer Research.

[99]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[100]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[101]  S. Pambuccian,et al.  Endobronchial ultrasound‐guided transbronchial needle aspiration cytology: a state of the art review , 2010, Cytopathology : official journal of the British Society for Clinical Cytology.

[102]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[103]  A. Mackensen,et al.  Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.

[104]  S. Khoury,et al.  A critical role for the programmed death ligand 1 in fetomaternal tolerance , 2005, The Journal of experimental medicine.

[105]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[106]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.